Biocept Q2 Revenues Grow on Increased Test Volume | GenomeWeb

NEW YORK (GenomeWeb) – Biocept reported Monday after the close of the market a year-over-year increase in second quarter revenues and commercial testing business volume, but also a higher net loss compared to the previous year.

Separately today, the firm announced a new collaboration with the University of California, Irvine to evaluate its liquid biopsy platform in guiding treatment for metastatic cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.